Previous 10 | Next 10 |
- Q3 FY2021 consolidated sales grow 27% over Q3 FY2020 – - Ongoing Part A of Phase 1 program evaluating TH1902 for sortilin-expressing cancers indicating better tolerability than docetaxel alone – MONTREAL, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies In...
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and C...
MONTREAL, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its third quarter...
- TMB-302 study results demonstrate that there was no difference in pharmacokinetics between IV Push and IV Infusion - - No serious adverse events observed – - sBLA filing planned for Q4 2021 - MONTREAL, Sept. 22, 2021 (GLOBE NEWSWIRE) --...
MONTREAL, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, ...
MONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical re...
MONTREAL, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer wi...
Theratechnologies Establishes New At-The-Market Facility Canada NewsWire MONTREAL , July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. (" Theratechnologies " or the " Company ") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the...
Theratechnologies Inc. (THTX) Q2 2021 Earnings Conference Call July 15, 2021 08:30 A.M. ET Company Participants Denis Boucher - VP, Communications and Corporate Affairs Paul Levesque - President and CEO Philippe Dubuc - SVP and CFO Christian Marsolais - SVP and CMO Conference Call Participant...
Theratechnologies (THTX): Q2 GAAP EPS of -$0.07 in-line.Revenue of $17.79M (+3.7% Y/Y) misses by $3.24M.Press Release For further details see: Theratechnologies EPS in-line, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...